Article
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial
Fecha
2016Registro en:
COOPER, D. A. et al. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial. PloS one, v. 11, n. 1, p. e0144917, 2016.
1932-6203
10.1371/journal.pone.0144917
Autor
Cooper, David A
Cordery, Damien V
Zajdenverg, Roberto
Ruxrungtham, Kiat
Arastéh, Keikawus
Bergmann, Frank
Neto, José L de Andrade
Scherer, Joseph
Chaves, Ricardo L
Robinson, Patrick
Study Team